Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 26;13(7):1039.
doi: 10.3390/biom13071039.

Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients

Affiliations

Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients

Stanley Du Preez et al. Biomolecules. .

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling multisystemic condition. The pathomechanism of ME/CFS remains unestablished; however, impaired natural killer (NK) cell cytotoxicity is a consistent feature of this condition. Calcium (Ca2+) is crucial for NK cell effector functions. Growing research recognises Ca2+ signalling dysregulation in ME/CFS patients and implicates transient receptor potential ion channel dysfunction. TRPM7 (melastatin) was recently considered in the pathoaetiology of ME/CFS as it participates in several Ca2+-dependent processes that are central to NK cell cytotoxicity which may be compromised in ME/CFS. TRPM7-dependent Ca2+ influx was assessed in NK cells isolated from n = 9 ME/CFS patients and n = 9 age- and sex-matched healthy controls (HCs) using live cell fluorescent imaging techniques. Slope (p < 0.05) was significantly reduced in ME/CFS patients compared with HCs following TRPM7 activation. Half-time of maximal response (p < 0.05) and amplitude (p < 0.001) were significantly reduced in the HCs compared with the ME/CFS patients following TRPM7 desensitisation. Findings from this investigation suggest that TRPM7-dependent Ca2+ influx is reduced with agonism and increased with antagonism in ME/CFS patients relative to the age- and sex-matched HCs. The outcomes reported here potentially reflect TRPM3 dysfunction identified in this condition suggesting that ME/CFS is a TRP ion channelopathy.

Keywords: calcium; chronic fatigue syndrome; myalgic encephalomyelitis; natural killer cell; transient receptor potential melastatin 7.

PubMed Disclaimer

Conflict of interest statement

The authors declare that this research was conducted in the absence of any commercial of financial relationships that could be construed as potential conflict of interest.

Figures

Figure 1
Figure 1
Ca2+ influx parameters from the stimulation of NK cells using 40 µM NTB. (a) Comparison of pooled slope values. (b) Comparison of pooled T1/2 values. (c) Comparison of pooled amplitude values. (d) Example Ca2+ influx recording with 40 µM NTB for TRPM7 activation and 1 µM ionomycin for non-specific Ca2+ influx in a HC. (e) Example Ca2+ influx recording with 40 µM NTB for TRPM7 activation and 1 µM ionomycin for non-specific Ca2+ influx in a ME/CFS patient. Data were collected from n = 9 HCs matched to n = 9 ME/CFS patients. The Ca2+ influx parameters were calculated from the smoothed (red) graph, which was generated by smoothing the raw (black) recording in OriginLabs displayed in (d,e). Values obtained from NTB stimulation for each cell were normalised to the ionomycin response curve within the same recording. The total number of cells analysed following the exclusion of definitive outliers (number of recordings excluded: HC = 14, ME/CFS = 25) are presented above the corresponding bar graph. All data are presented as mean ± SD with significance as determined using independent Mann–Whitney U tests. * p < 0.05. Abbreviations: calcium (Ca2+), healthy control (HC), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), natural killer (NK), naltriben (NTB), half-time of maximum response (T1/2).
Figure 2
Figure 2
Ca2+ influx parameters from the inhibition and desensitisation of NK cells using 6 µM NS8593. (a) Comparison of pooled slope values. (b) Comparison of pooled T1/2 values. (c) Comparison of pooled amplitude values. (d) Example Ca2+ influx recording with 6 µM NS8593 for TRPM7 activation, 6 µM NS8593 + 40 µM NTB for TRPM7 desensitisation, followed by 40 µM NTB for TRPM7 activation and 1 µM ionomycin for non-specific Ca2+ influx in a HC. (e) Example Ca2+ influx recording with 6 µM NS8593 for TRPM7 activation, 6 µM NS8593 + 40 µM NTB for TRPM7 desensitisation, followed by 40 µM NTB for TRPM7 activation and 1 µM ionomycin for non-specific Ca2+ influx in a ME/CFS patient. Data were collected from n = 9 HCs matched to n = 9 ME/CFS patients. The Ca2+ influx parameters were calculated from the smoothed (red) graph, which was generated by smoothing the raw (black) recording in OriginLabs displayed in (d,e). Values obtained from NS8593 inhibition for each cell were normalised to the ionomycin response curve within the same recording. The total number of cells analysed following the exclusion of definitive outliers (number of recordings excluded: HC = 6, ME/CFS = 7) are presented above the corresponding bar graph. All data are presented as mean ± SD with significance as determined using independent Mann–Whitney U tests. * p < 0.05, *** p < 0.001. Abbreviations: calcium (Ca2+), healthy control (HC), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), natural killer (NK), NS8593 (NS), naltriben (NTB), half-time of maximum response (T1/2).

Similar articles

Cited by

References

    1. Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T., Staines D., Powles A.P., Speight N., Vallings R., et al. Myalgic encephalomyelitis: International Consensus Criteria. J. Intern. Med. 2011;270:327–338. doi: 10.1111/j.1365-2796.2011.02428.x. - DOI - PMC - PubMed
    1. Clayton E.W. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An IOM Report on Redefining an Illness. JAMA. 2015;313:1101–1102. doi: 10.1001/jama.2015.1346. - DOI - PubMed
    1. Abdulla J., Torpy B.D. Chronic Fatigue Syndrome. In: De Groot L.J., Chrousos G., Dungan K., Feingold K.R., Grossman A., Hershman J.M., editors. Endotext. MDText.com, Inc.; South Dartmouth, MA, USA: 2000.
    1. Bozzini S., Albergati A., Capelli E., Lorusso L., Gazzaruso C., Pelissero G., Falcone C. Cardiovascular characteristics of chronic fatigue syndrome. Biomed. Rep. 2018;8:26–30. doi: 10.3892/br.2017.1024. - DOI - PMC - PubMed
    1. Monro J.A., Puri B.K. A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications. Mol. Neurobiol. 2018;55:7377–7388. doi: 10.1007/s12035-018-0928-9. - DOI - PMC - PubMed

Publication types

MeSH terms